Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease
| Autor: | Harikrishnan Sivadasanpillai, Reema George, Jissa Vinoda Thulaseedharan, Jaganmohan Tharakan, Jayakumari Narayani, Anugya Bhatt |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Platelets Male medicine.medical_specialty Homocysteine Clinical Biochemistry Coronary Artery Disease 030204 cardiovascular system & hematology Coronary Angiography Fibrinogen Asymptomatic Gastroenterology Coronary artery disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Von Willebrand factor Internal medicine Humans Medicine 030212 general & internal medicine Platelet activation Acute Coronary Syndrome Molecular Biology biology business.industry Antithrombin Cell Biology General Medicine Middle Aged Platelet Activation medicine.disease P-Selectin Gene Expression Regulation chemistry Immunology biology.protein medicine.symptom business Plasminogen activator Follow-Up Studies medicine.drug |
| Zdroj: | Molecular and Cellular Biochemistry. 419:125-133 |
| ISSN: | 1573-4919 0300-8177 |
| Popis: | P-selectin (CD62p) exposure is an established marker for platelet activation. P-selectin exposure can trigger variety of thrombotic and inflammatory reactions. In patients with coronary artery disease (CAD), platelets are activated, and hence, there is increased P-selectin exposure. The role of P-selectin exposure in patients on treatment with statins and anti-platelets is conflicting. A case–control study was performed to determine P-selectin exposure in consecutively recruited 142 patients (age ≤ 55 years) with angiographically proven CAD on treatment and 92 asymptomatic controls. P-selectin exposure was determined by flow cytometry. Data on conventional risk factors were obtained along with estimation of levels of thrombotic [fibrinogen, lipoprotein (a), tissue plasminogen activator, plasminogen activator inhibitor-1, homocysteine and von Willebrand factor] and anti-thrombotic factors (antithrombin III). The P-selectin exposure was compared among patient groups who had different modes of presentation of CAD and categories of CAD disease severity. The patients were followed up for a period of 26 months. The results indicate that P-selectin exposure was significantly elevated in patients (mean ± SD 9.24 ± 11.81) compared to controls (mean ± SD 1.48 ± 2.85) with p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink